CDH13, cadherin 13, 1012

N. diseases: 205; N. variants: 47
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0282606
Disease: Myomatous neoplasm
Myomatous neoplasm 		0.010 Biomarker disease BEFREE Simultaneous flow cytometric quantitation of DNA content and the proliferation-associated nuclear antigen p105 was performed on 41 gastrointestinal smooth muscle neoplasms and the results were correlated with histologic features. 3202248 1988
CUI: C0024299
Disease: Lymphoma
Lymphoma 		0.020 Biomarker group BEFREE We have performed two-color flow cytometric quantitation of nuclear antigen p105 and DNA content in nuclear suspensions from 80 paraffin-embedded lymphomas. 2569301 1989
CUI: C0019829
Disease: Hodgkin Disease
Hodgkin Disease 		0.010 Biomarker disease BEFREE Flow cytometric measurements of proliferation-associated nuclear antigen p105 and DNA content in non-Hodgkin's lymphomas. 2569301 1989
CUI: C0079740
Disease: High Grade Lymphoma (neoplasm)
High Grade Lymphoma (neoplasm) 		0.010 AlteredExpression disease BEFREE High-grade lymphomas with diploid DNA histograms tended to express high levels of p105 in all phases of the cell cycle. 2569301 1989
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 AlteredExpression group BEFREE Nuclear antigen quantitation of diploid tumors showed a wide range of p105 expression in G0G1 cells, suggesting that, within each tumor, the cells are heterogeneous with respect to proliferative activity. 2377285 1990
CUI: C0017638
Disease: Glioma
Glioma 		0.020 AlteredExpression disease BEFREE Aneuploid nuclei of glial tumors showed enhanced expression of p105 relative to diploid cells of the same specimen. 2377285 1990
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.100 Biomarker group BEFREE Flow cytometric quantitation of the proliferation-associated nuclear antigen p105 was done on cancer cell suspensions from 114 advanced gastric cancers and correlated with clinical behavior. 1913456 1991
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.100 Biomarker group BEFREE Flow cytometric quantitation of the proliferation-associated nuclear antigen p105 was done on cancer cell suspensions from 114 advanced gastric cancers and correlated with clinical behavior. 1913456 1991
CUI: C0007097
Disease: Carcinoma
Carcinoma 		0.050 Biomarker group BEFREE The expression of proliferation-associated nuclear antigen p105 of gastric carcinomas was studied by multiparameter flow cytometric and immunohistochemical technique. 2015552 1991
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach 		0.030 Biomarker disease BEFREE Flow cytometric quantitation of the proliferation-associated nuclear antigen p105 was done on cancer cell suspensions from 114 advanced gastric cancers and correlated with clinical behavior. 1913456 1991
CUI: C0024299
Disease: Lymphoma
Lymphoma 		0.020 Biomarker group BEFREE Although p105 content tended to be higher in HAL than in an AIDS-related complex (ARC)-associated hyperplastic lymph node control, no statistically significant associations were found between p105 content and proliferative activity or the number of mitoses per 10 high-power fields. 1677032 1991
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma 		0.020 Biomarker disease BEFREE The expression of proliferative-associated nuclear antigen p105 in gastric carcinoma. 2015552 1991
CUI: C0001857
Disease: AIDS related complex
AIDS related complex 		0.010 Biomarker disease BEFREE Although p105 content tended to be higher in HAL than in an AIDS-related complex (ARC)-associated hyperplastic lymph node control, no statistically significant associations were found between p105 content and proliferative activity or the number of mitoses per 10 high-power fields. 1677032 1991
CUI: C0340782
Disease: Hyperplastic lymph node
Hyperplastic lymph node 		0.010 Biomarker disease BEFREE Although p105 content tended to be higher in HAL than in an AIDS-related complex (ARC)-associated hyperplastic lymph node control, no statistically significant associations were found between p105 content and proliferative activity or the number of mitoses per 10 high-power fields. 1677032 1991
CUI: C0023449
Disease: Acute lymphocytic leukemia
Acute lymphocytic leukemia 		0.010 Biomarker disease BEFREE Interestingly, p49/p100 as well as p105 maps to regions associated with certain types of acute lymphoblastic leukemia. 1612589 1992
CUI: C1961102
Disease: Precursor Cell Lymphoblastic Leukemia Lymphoma
Precursor Cell Lymphoblastic Leukemia Lymphoma 		0.010 Biomarker disease BEFREE Interestingly, p49/p100 as well as p105 maps to regions associated with certain types of acute lymphoblastic leukemia. 1612589 1992
CUI: C0023418
Disease: leukemia
leukemia 		0.010 AlteredExpression disease BEFREE We conclude that abnormal expression of RB with absence of p105 or strongly reduced p105 levels occurs frequently in myelomonocytic and monoblastic leukaemias and that this may be correlated with a more malignant course of the disease. 8485048 1993
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 Biomarker group BEFREE The objectives of this Radiation Therapy Oncology Group (RTOG) protocol (91-08) were: (1) to correlate tumor proliferative potential estimated using the p105 assay and deoxyribonucleic acid (DNA) analysis with treatment outcome in patients irradiated for advanced squamous cell carcinoma of the head and neck; and (2) to evaluate the potential of p105 labeling indices as a predictive assay. 7913703 1994
CUI: C0007137
Disease: Squamous cell carcinoma
Squamous cell carcinoma 		0.060 Biomarker disease BEFREE These results suggest that flow cytometric quantitation of the proliferation-associated nuclear antigen p105 and DNA content of pretreatment tumor biopsies may be a potentially useful predictive assay in patients irradiated for advanced squamous cell carcinomas of the head and neck. 7913703 1994
CUI: C0024305
Disease: Lymphoma, Non-Hodgkin
Lymphoma, Non-Hodgkin 		0.010 AlteredExpression disease BEFREE Twenty six high grade NHL samples (58%) showed no p105 expression. 8289506 1994
CUI: C1168401
Disease: Squamous cell carcinoma of the head and neck
Squamous cell carcinoma of the head and neck 		0.010 Biomarker disease BEFREE The objectives of this Radiation Therapy Oncology Group (RTOG) protocol (91-08) were: (1) to correlate tumor proliferative potential estimated using the p105 assay and deoxyribonucleic acid (DNA) analysis with treatment outcome in patients irradiated for advanced squamous cell carcinoma of the head and neck; and (2) to evaluate the potential of p105 labeling indices as a predictive assay. 7913703 1994
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 AlteredExpression group BEFREE Flow cytometry was also used to measure DNA Index and tumor S-phase fraction, in some cases using multiparameter analysis of isolated nuclei to determine DNA content and the level of the proliferation-associated antigen, p105. 8529468 1995
CUI: C0023470
Disease: Myeloid Leukemia
Myeloid Leukemia 		0.010 AlteredExpression disease BEFREE The results of different investigators show that lack of p105 expression is relatively common in human myeloid leukemias, especially in monocytic leukemias. 7773151 1995
CUI: C3854222
Disease: Human immunodeficiency virus (HIV) II infection category B1
Human immunodeficiency virus (HIV) II infection category B1 		0.010 Biomarker disease BEFREE Regulation of I kappa B alpha and p105 in monocytes and macrophages persistently infected with human immunodeficiency virus. 7853483 1995
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.100 Biomarker group BEFREE Flow cytometric study of the proliferation-associated nuclear antigen p105 was done on cancer cell suspensions from 75 patients with renal cell carcinomas. 8756377 1996